Oral phosphate binders in patients with kidney failure.
Tonelli
Marcello
M
Department of Medicine, University of Alberta, Edmonton, Canada. mtonelli-admin@med.ualberta.ca
Pannu
Neesh
N
Manns
Braden
B
D017610:Calcium Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D002614:Chelating Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D054559:Hyperphosphatemia / Q000178:diet therapy / Q000188:drug therapy* / Q000378:metabolism; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000378:metabolism; D007811:Lanthanum / Q000009:adverse effects / Q000627:therapeutic use; D010710:Phosphates / Q000378:metabolism*; D011073:Polyamines / Q000009:adverse effects / Q000627:therapeutic use; D000069603:Sevelamer
D017610:Calcium Compounds; D002614:Chelating Agents; D010710:Phosphates; D011073:Polyamines; C119467:lanthanum carbonate; D007811:Lanthanum; D000069603:Sevelamer